BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
BCRX earnings call for the period ending March 31, 2021.
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were soaring 14.5% higher as of 10:51 a.m. EDT on Thursday. BioCryst stated that the majority of these sales came from new patients who switched to Orladeyo from other medications or from acute-only treatment. In addition to its better-than-expected sales, BioCryst also announced that it's reached an agreement with the U.S. Food and Drug Administration (FDA) to use change from baseline in hemoglobin as the primary endpoint for its planned pivotal clinical studies evaluating BCX9930 in treating rare disease paroxysmal nocturnal hemoglobinuria (PNH).